Xanthelasma, Cholesterol and Weight: What the Eyelid Deposits Signal

Xanthelasma are flat, soft, yellowish patches on the eyelids, most often near the inner corner of the upper lid. They are the most common type of skin xanthoma, a deposit of cholesterol-filled cells in the skin ^[2]. In a Danish population study of more than 12,000 adults, 4.4% had them, and people with xanthelasma had about 1.5 times the risk of a heart attack over the following decades, even after accounting for their cholesterol levels ^[1]. This review covers what the patches are linked to, how much body weight has to do with it, what weight loss and GLP-1 drugs do to cholesterol, and how removal options compare.

The honest summary

• Xanthelasma can be a heart-risk signal. In the Copenhagen City Heart Study, they predicted more heart attacks, more heart disease and higher death rates, independent of cholesterol ^[1].
• Not every study agrees. An Israeli screening study found no difference in cholesterol or heart disease between people with and without xanthelasma ^[4].
• LDL cholesterol looks like the driver, not body weight. A genetic study linked higher LDL and total cholesterol to xanthelasma, but found no link with BMI, blood sugar or blood pressure ^[5].
• Weight loss lowers LDL, but only modestly. Trials show about 1.3 to 1.7 mg/dL less LDL per kilogram lost ^[9], and semaglutide lowered LDL by about 6 mg/dL in trials of people without diabetes ^[10].
• No study shows that weight loss or a GLP-1 drug clears the patches. Removal is done with surgery, lasers or chemical peels ^[12].
• The practical step is a cholesterol test. The patches are a reason to check your lipids and overall heart risk, whatever you decide about removal.

What xanthelasma is

Under the microscope, xanthelasma are clusters of foam cells, immune cells loaded with fat droplets, sitting in the upper layer of the skin ^[2]. They usually appear as soft yellow plaques on the eyelids, most often near the inner corner of the upper lid ^[2]. A review of the condition lists high blood lipids, thyroid problems and diabetes as known triggers ^[2].

The patches themselves are a skin finding. The reason doctors take them seriously is what they may say about cholesterol and the arteries. Other yellow eyelid bumps exist, so a doctor should confirm the diagnosis before any treatment.

Xanthelasma and cholesterol

A 2020 meta-analysis pooled 15 case-control studies with 854 people with xanthelasma ^[3]. Compared with people without them, they had higher total cholesterol, higher LDL cholesterol, higher apolipoprotein B (the protein carried by each LDL particle) and lower apolipoprotein A1. Their carotid artery walls were also thicker on ultrasound, an early sign of atherosclerosis. The authors concluded that people with xanthelasma should be monitored for heart disease risk. For more on apoB and why it matters, see GLP-1 drugs and apoB, non-HDL and Lp(a).

A large screening study from Israel reached a different conclusion ^[4]. Among 35,452 adults examined at a screening center, 203 (0.6%) had xanthelasma. Compared with 2,030 people of the same age and sex, they had similar rates of diagnosed high cholesterol (42% versus 46%), similar use of cholesterol-lowering drugs, similar LDL levels (median 125 versus 120 mg/dL) and similar rates of heart disease (8.9% versus 10%). The authors questioned how much xanthelasma tells you about overall risk.

One way to reconcile these results is that cholesterol is normal in many people with xanthelasma: in the Israeli study, fewer than half had a diagnosis of high cholesterol ^[4]. The link may also show up more clearly in some populations than others. Either way, a lipid panel is the only way to know where you stand.

What xanthelasma may signal about heart risk

The strongest long-term data come from the Copenhagen City Heart Study, which examined 12,745 adults free of heart disease in 1976 to 1978 and followed them for up to 33 years ^[1]. After adjusting for the usual risk factors, including cholesterol and triglycerides, people with xanthelasma had a higher risk of heart attack (hazard ratio 1.48), of ischemic heart disease (1.39), of severe atherosclerosis (odds ratio 1.69) and of death (1.14). They did not have a higher risk of ischemic stroke. In men aged 70 to 79, the 10-year risk of ischemic heart disease was 53% with xanthelasma versus 41% without; in women of the same age, 35% versus 27%.

Two recent US health-record studies point the same way, with different sizes of effect. One matched 20,048 people with xanthelasma to 20,048 without and found a higher risk of later high cholesterol (HR 1.38) and of major cardiovascular events (HR 1.26), and a small increase in deaths (HR 1.09) ^[6]. Another, which compared people with xanthelasma with people seen for age-related near-sight changes, found about twice the 10-year rate of heart attack (3.13% versus 1.73%) and of stroke (3.00% versus 1.53%) ^[7]. Health-record studies depend on diagnosis codes and cannot rule out that people with a xanthelasma diagnosis differ in other ways.

Is body weight part of the link?

Less than you might expect. A 2024 Mendelian randomization study used genetic variants as a natural experiment to test which traits might cause xanthelasma ^[5]. Genetically higher total and LDL cholesterol were linked to xanthelasma; HDL cholesterol and triglycerides were not. Genetically higher BMI, fasting glucose, type 2 diabetes and blood pressure were not linked either. That points to LDL cholesterol, rather than body weight itself, as the main driver.

Clinical studies are mixed. In an Indian case-control study of 106 people with xanthelasma and 106 matched controls, metabolic syndrome and abnormal lipids were somewhat more common in the xanthelasma group, but neither difference was statistically clear (odds ratios 1.6 and 1.4), and overweight or obesity was actually less common among people with xanthelasma (odds ratio 0.2) ^[8]. Within the xanthelasma group, more extensive patches and diabetes went with metabolic syndrome. In other words, many people with xanthelasma are not overweight.

Weight still matters for the bigger picture. Losing weight lowers triglycerides and raises HDL ^[9], and the same heart risk that xanthelasma may signal is shaped by weight, blood pressure and blood sugar. A related skin sign of insulin resistance, darkened skin folds, is covered in skin tags and acanthosis nigricans.

What weight loss and GLP-1 drugs do to cholesterol

A 2020 meta-analysis of 73 randomized trials with 32,496 adults with overweight or obesity measured how lipids change with weight loss ^[9]. After 12 months of diet and exercise programs, each kilogram lost went with about 1.3 mg/dL lower LDL, 4.0 mg/dL lower triglycerides and 0.5 mg/dL higher HDL. With weight-loss drugs, each kilogram lost went with about 1.7 mg/dL lower LDL. Losing 10 kg (22 lb) would therefore be expected to lower LDL by roughly 13 to 17 mg/dL, a real but modest change compared with what cholesterol drugs achieve.

For semaglutide 2.4 mg, a 2025 meta-analysis of four trials lasting 68 weeks or more in adults without diabetes found LDL about 6 mg/dL lower, total cholesterol about 6.4 mg/dL lower and VLDL cholesterol about 15 mg/dL lower than with placebo, with a small rise in HDL ^[10]. How these drugs change triglycerides is covered in GLP-1 drugs and triglycerides.

The heart benefit of semaglutide does not rest on cholesterol alone. In the SELECT trial, 17,604 adults with heart disease and a BMI of 27 or more, but no diabetes, were assigned to semaglutide 2.4 mg or placebo ^[11]. Over about 40 months, heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide versus 8.0% on placebo (HR 0.80). SELECT did not enroll people because of xanthelasma and did not report on it. More detail is in the SELECT trial review.

Xanthelasma removal: what the evidence shows

Treatment options include surgical excision, cryotherapy, chemical peels with trichloroacetic acid (TCA), radiofrequency and several lasers ^[2]. A 2023 systematic review of 49 studies with 1,329 patients found that most studies were retrospective and lacked a comparison group ^[12]. CO2 and Er:YAG lasers, the most studied, gave more than 75% improvement in over 90% and 80% of patients respectively. Changes in skin color were the most common complication. The reviewers judged surgery more suitable for larger, deeper patches and lasers or electrosurgery for smaller, superficial ones.

The only head-to-head randomized trial found here treated one eye of each patient with excision and the other with 70% TCA ^[13]. At 12 weeks, all 36 excised sides were completely clear versus 8 of 36 (22%) of the TCA-treated sides, and skin color changes were more common after TCA (75% versus 42%). The trial was small and short, and limited to patches covering no more than a third of the eyelid.

Patches can come back. In a series of 295 patients treated with CO2 laser excision, more than 99% of smaller lesions cleared, and 6.8% recurred within a year, more often when the patch was taller than 2 mm ^[14]. Scarring occurred in 4.4% and lightening or darkening of the skin in about 8%. Because recurrence and new patches are possible, removal works best alongside, not instead of, a check of cholesterol and heart risk.

Practical guidance

• Get a lipid panel. Xanthelasma is linked to higher LDL and apoB in many studies ^[3], and it may signal heart risk even when cholesterol is normal ^[1].
• Ask about your overall heart risk, not only your cholesterol number, especially if you also smoke, have high blood pressure or have diabetes.
• Do not expect weight loss to clear the patches. It lowers LDL modestly ^[9] and helps heart risk in other ways, but it has not been tested as a treatment for xanthelasma.
• If LDL is high, the main tools are cholesterol-lowering drugs, with weight loss and diet as support.
• For removal, see a dermatologist or oculoplastic surgeon. Larger patches usually do better with surgery, smaller ones with laser or other methods ^[12].